Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
07:24am, Monday, 10'th Feb 2025
Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025.
Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise
01:30pm, Wednesday, 05'th Feb 2025
The Investment Committee give you their top stocks to watch for the second half.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
07:10am, Tuesday, 04'th Feb 2025
Vertex Pharmaceuticals (VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Ve
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
08:06am, Sunday, 02'nd Feb 2025
Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
05:35am, Sunday, 02'nd Feb 2025
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, d
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
10:17pm, Saturday, 01'st Feb 2025
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2
Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
08:00am, Saturday, 01'st Feb 2025
Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opio
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
01:50pm, Friday, 31'st Jan 2025
JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vert
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
10:36am, Friday, 31'st Jan 2025
Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decad
Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
10:33am, Friday, 31'st Jan 2025
CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
06:59am, Friday, 31'st Jan 2025
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
06:52am, Friday, 31'st Jan 2025
CNBC's Becky Quick reports on the latest news.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
04:35am, Friday, 31'st Jan 2025
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.
